| Dr Richard C Evans, MD | |
|
110 Irving St Nw, Washington, DC 20010-2976 | |
| (301) 946-5100 | |
| (301) 929-0348 |
| Full Name | Dr Richard C Evans |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 26 Years |
| Location | 110 Irving St Nw, Washington, District Of Columbia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1578582995 | NPI | - | NPPES |
| 0152 | Other | DC | CAREFIRST BCBS |
| 7182379 | Other | DC | AETNA NON HMO |
| 3570017 | Other | DC | AETNA HMO |
| 666685 | Other | DC | NCPPO |
| 139702 | Other | VA | VIRGINIA BCBS |
| 242824 | Other | DC | KAISER |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | MD035015 (District Of Columbia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Adventist Healthcare White Oak Medical Center | Silver spring, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| First Colonies Anesthesia Associates, Llc | 8426039744 | 359 |
| First Colonies Anesthesia Associates, Llc | 8426039744 | 359 |
News Archive
Protalix BioTherapeutics, Inc., announced today positive preliminary data from the first 15 patients that completed the Company's nine month, worldwide, multi-center, open-label, switchover trial of taliglucerase alfa for the treatment of Gaucher disease under a protocol cleared by the U.S. Food and Drug Administration (FDA). The data indicate that patients can safely be switched to taliglucerase alfa from imiglucerase (Cerezyme®).
Synthetic antidepressants present a narrow spectrum and side effects following long-term application. Recently, medical practitioners have shown interest in the use of Chinese medicines for the treatment of diseases and in the adjustment of the human response to stress.
Mallinckrodt plc, a leading specialty biopharmaceutical company, announced today that it has closed the sale of its global contrast media and delivery systems (CMDS) business to Guerbet in a transaction valued at approximately $270 million.
MIT researchers have developed a wireless, private way to monitor a person's sleep postures - whether snoozing on their back, stomach, or sides - using reflected radio signals from a small device mounted on a bedroom wall.
Phase Holographic Imaging (PHI) today announces a collaboration agreement with Northeastern University of Boston.
› Verified 2 days ago
| Entity Name | First Colonies Anesthesia Associates, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740218767 PECOS PAC ID: 8426039744 Enrollment ID: O20040607001456 |
News Archive
Protalix BioTherapeutics, Inc., announced today positive preliminary data from the first 15 patients that completed the Company's nine month, worldwide, multi-center, open-label, switchover trial of taliglucerase alfa for the treatment of Gaucher disease under a protocol cleared by the U.S. Food and Drug Administration (FDA). The data indicate that patients can safely be switched to taliglucerase alfa from imiglucerase (Cerezyme®).
Synthetic antidepressants present a narrow spectrum and side effects following long-term application. Recently, medical practitioners have shown interest in the use of Chinese medicines for the treatment of diseases and in the adjustment of the human response to stress.
Mallinckrodt plc, a leading specialty biopharmaceutical company, announced today that it has closed the sale of its global contrast media and delivery systems (CMDS) business to Guerbet in a transaction valued at approximately $270 million.
MIT researchers have developed a wireless, private way to monitor a person's sleep postures - whether snoozing on their back, stomach, or sides - using reflected radio signals from a small device mounted on a bedroom wall.
Phase Holographic Imaging (PHI) today announces a collaboration agreement with Northeastern University of Boston.
› Verified 2 days ago
| Entity Name | Emergency Medicine Associates Pa Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134117393 PECOS PAC ID: 8022914522 Enrollment ID: O20070919000389 |
News Archive
Protalix BioTherapeutics, Inc., announced today positive preliminary data from the first 15 patients that completed the Company's nine month, worldwide, multi-center, open-label, switchover trial of taliglucerase alfa for the treatment of Gaucher disease under a protocol cleared by the U.S. Food and Drug Administration (FDA). The data indicate that patients can safely be switched to taliglucerase alfa from imiglucerase (Cerezyme®).
Synthetic antidepressants present a narrow spectrum and side effects following long-term application. Recently, medical practitioners have shown interest in the use of Chinese medicines for the treatment of diseases and in the adjustment of the human response to stress.
Mallinckrodt plc, a leading specialty biopharmaceutical company, announced today that it has closed the sale of its global contrast media and delivery systems (CMDS) business to Guerbet in a transaction valued at approximately $270 million.
MIT researchers have developed a wireless, private way to monitor a person's sleep postures - whether snoozing on their back, stomach, or sides - using reflected radio signals from a small device mounted on a bedroom wall.
Phase Holographic Imaging (PHI) today announces a collaboration agreement with Northeastern University of Boston.
› Verified 2 days ago
| Entity Name | Us Anesthesia Partners Of Dc Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710598859 PECOS PAC ID: 7719395888 Enrollment ID: O20210412000137 |
News Archive
Protalix BioTherapeutics, Inc., announced today positive preliminary data from the first 15 patients that completed the Company's nine month, worldwide, multi-center, open-label, switchover trial of taliglucerase alfa for the treatment of Gaucher disease under a protocol cleared by the U.S. Food and Drug Administration (FDA). The data indicate that patients can safely be switched to taliglucerase alfa from imiglucerase (Cerezyme®).
Synthetic antidepressants present a narrow spectrum and side effects following long-term application. Recently, medical practitioners have shown interest in the use of Chinese medicines for the treatment of diseases and in the adjustment of the human response to stress.
Mallinckrodt plc, a leading specialty biopharmaceutical company, announced today that it has closed the sale of its global contrast media and delivery systems (CMDS) business to Guerbet in a transaction valued at approximately $270 million.
MIT researchers have developed a wireless, private way to monitor a person's sleep postures - whether snoozing on their back, stomach, or sides - using reflected radio signals from a small device mounted on a bedroom wall.
Phase Holographic Imaging (PHI) today announces a collaboration agreement with Northeastern University of Boston.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Richard C Evans, MD 11510 Georgia Ave, Suite 206, Wheaton, MD 20902-1925 Ph: (301) 946-5100 | Dr Richard C Evans, MD 110 Irving St Nw, Washington, DC 20010-2976 Ph: (301) 946-5100 |
News Archive
Protalix BioTherapeutics, Inc., announced today positive preliminary data from the first 15 patients that completed the Company's nine month, worldwide, multi-center, open-label, switchover trial of taliglucerase alfa for the treatment of Gaucher disease under a protocol cleared by the U.S. Food and Drug Administration (FDA). The data indicate that patients can safely be switched to taliglucerase alfa from imiglucerase (Cerezyme®).
Synthetic antidepressants present a narrow spectrum and side effects following long-term application. Recently, medical practitioners have shown interest in the use of Chinese medicines for the treatment of diseases and in the adjustment of the human response to stress.
Mallinckrodt plc, a leading specialty biopharmaceutical company, announced today that it has closed the sale of its global contrast media and delivery systems (CMDS) business to Guerbet in a transaction valued at approximately $270 million.
MIT researchers have developed a wireless, private way to monitor a person's sleep postures - whether snoozing on their back, stomach, or sides - using reflected radio signals from a small device mounted on a bedroom wall.
Phase Holographic Imaging (PHI) today announces a collaboration agreement with Northeastern University of Boston.
› Verified 2 days ago
Dr. Fay Horng, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 110 Irving St Nw, Washington, DC 20010 Phone: 202-877-7504 | |
Dr. Matthew Mueller, DO, MPH Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 110 Irving St Nw, Washington, DC 20010 Phone: 202-877-7000 | |
Dr. Shane Zamani, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 900 23rd St Nw, Washington, DC 20037 Phone: 202-715-4750 | |
Dr. Thomas Edward Borsari, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 50 Irving St Nw, Dept Of Anesthesiology, Washington, DC 20422 Phone: 202-745-8000 | |
Alexis Lambros, CAA Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 111 Michigan Ave Nw, Washington, DC 20010 Phone: 202-476-2025 | |
Susan Verghese, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 111 Michigan Ave Nw, Washington, DC 20010 Phone: 202-884-2025 | |
Joan Threlfall, Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3800 Reservoir Rd Nw, Washington, DC 20007 Phone: 202-444-8640 |